Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 2/20 | 0.72 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.72 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.72 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387062 | 0.84 | AKR1C3 (1.00) | AKR1C4AKR1C3AKR1C2AKR1C1CYP3A4 | |
| SCHEMBL330545 | 0.84 | AKR1C3 (1.00) | AKR1C4AKR1C3AKR1C2AKR1C1CYP3A4 | |
| SCHEMBL10701348 | 0.82 | AKR1C3 (0.61) | AKR1C4AKR1C3AKR1C2AKR1C1MEN1 | |
| SCHEMBL895511 | 0.82 | AKR1C4 (0.67) | AKR1C4AKR1C3AKR1C2AKR1C1CYP3A4 | |
| SCHEMBL9019697 | 0.82 | AKR1C3 (0.96) | AKR1C4AKR1C3AKR1C2AKR1C1CYP3A4 | |
| Hydrochloric Acid SCHEMBL11781789 | 0.82 | AKR1C3 (0.96) | AKR1C4AKR1C3AKR1C2AKR1C1CYP3A4 | |
| SCHEMBL9398455 | 0.82 | AKR1C3 (0.96) | AKR1C4AKR1C3AKR1C2AKR1C1CYP3A4 | |
| SCHEMBL9398447 | 0.82 | AKR1C3 (0.96) | AKR1C4AKR1C3AKR1C2AKR1C1CYP3A4 | |
| SCHEMBL11800079 | 0.82 | AKR1C4 (0.67) | AKR1C4AKR1C3AKR1C2AKR1C1CYP3A4 | |
| SCHEMBL11760933 | 0.82 | AKR1C4 (0.67) | AKR1C4AKR1C3AKR1C2AKR1C1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610890-B1 | Treatment and/or prevention of diabetic complications; such as 3,3',4,4',5,5'-hexabromo-2,2'-dihydroxy-oxydiphenyl | O.N.C.E.-(ORGANIZACION NACIONAL DE CICGOS) (ES) | 2003-08-26 | — | — | US | disclosed |
| US-20030153628-A1 | ALDOSE REDUCTASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS | O.N.C.E.-(ORGANIZACION NACIONAL DE CIEGOS) (ES) | 2003-08-14 | — | — | US | disclosed |
| EP-1137621-A1 | ALDOSE REDUCTASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS | ORGANIZACION NACIONAL DE CIEGOS ESPANOLES - ONCE - (ES) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000035848-A1 | ALDOSE REDUCTASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS | O.N.C.E. - (ORGANIZACION NACIONAL DE CIEGOS) (ES) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153628-A1 | ALDOSE REDUCTASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS | AKR1A1, AKR1B1, AKR1C2 | AKR1C4 5/4885AKR1C3 8/4885AKR1C2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.